Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.58 USD
-0.12 (-7.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.60 +0.02 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GANX 1.58 -0.12(-7.06%)
Will GANX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 9th
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GANX
GANX Fell Below 50 Day Moving Average on September 19
GANX Crossed Above 50 Day Moving Average on September 19
GANX forms Directional Movement Crossover Bearish on September 17
Gain Therapeutics (GANX) Extends Phase 1b Study for Parkinson's Treatment
Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s